Brisbane, CA, United States
Brisbane, CA, United States

Time filter

Source Type

Patent
Intermune Inc. | Date: 2016-12-01

The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.


Patent
InterMune Inc. | Date: 2017-03-22

The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.


Patent
Intermune Inc. | Date: 2017-01-23

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.


Patent
Intermune Inc. | Date: 2016-12-22

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.


Patent
InterMune Inc. | Date: 2016-12-21

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.


Patent
Intermune Inc. | Date: 2017-03-22

Provided herein are, inter alia, methods and biomarkers to determine if a patient has or is at risk for developing an LPA-associated disease, to indicate the progressiveness of the disease, and/or to facilitate evaluation of responsiveness to therapy. Compositions and kits including the biomarker proteins and biomarker RNAs provided herein are further provided.


Patent
Intermune Inc. | Date: 2017-02-08

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.


Patent
Intermune Inc. | Date: 2016-05-06

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.


Patent
InterMune Inc. | Date: 2016-08-10

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.


Patent
Intermune Inc. | Date: 2016-06-10

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Loading InterMune Inc. collaborators
Loading InterMune Inc. collaborators